{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T11:13:26Z","timestamp":1769858006183,"version":"3.49.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jphs.2025.05.018","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T22:43:36Z","timestamp":1748385816000},"page":"363-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Additive effects of mirabegron on muscarinic receptor binding and on relaxation of cholinergic detrusor muscle contraction by antimuscarinics"],"prefix":"10.1016","volume":"158","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5915-9863","authenticated-orcid":false,"given":"Shizuo","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masae","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Maruyama-Fumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Kagota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Shinozuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2025.05.018_bib1","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-Aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective \u03b23-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2025.05.018_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.jphs.2025.05.018_bib3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/iju.13868","article-title":"Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: a multicenter, randomized study in Japan (MILAI II study)","volume":"26","author":"Yamaguchi","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.jphs.2025.05.018_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ejphar.2012.11.060","article-title":"The novel \u03b23-adrenoceptor agonist mirabegron reduces carbachol-induced contractile activity in detrusor tissue from patients with bladder outflow obstruction with or without detrusor overactivity","volume":"699","author":"Sval\u00f8","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.018_bib5","first-page":"66","article-title":"\u03b23-adrenoceptor agonists for overactive bladder syndrome: role of translational pharmacology in a repositioning clinical drug development project Pharmacol","volume":"159","author":"Michel","year":"2016","journal-title":"Ther."},{"key":"10.1016\/j.jphs.2025.05.018_bib6","first-page":"833","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs (Basel)"},{"key":"10.1016\/j.jphs.2025.05.018_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jphs.2025.05.018_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.3109\/00498254.2012.700140","article-title":"In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective \u03b23-adrenoceptor agonist","volume":"42","author":"Takusagawa","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jphs.2025.05.018_bib9","first-page":"957","volume":"42","author":"Takusagawa","year":"2012"},{"key":"10.1016\/j.jphs.2025.05.018_bib10","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bph.13367","article-title":"Mirabegron relaxes urethral smooth muscle by a dual mechanism involving \u03b23-adrenoceptor activation and \u03b11-adrenoceptor blockade","volume":"173","author":"Alexandre","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.018_bib11","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1111\/bph.13897","article-title":"The \u03b23-adrenoceptor agonist mirabegron increases human atrial force through \u03b21-adrenoceptors: an indirect mechanism?","volume":"174","author":"Mo","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.018_bib12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13318-016-0350-5","article-title":"Pharmacokinetic interactions between mirabegron and metformin, warfarin, digoxin or combined oral contraceptives","volume":"42","author":"Groen-Wijnberg","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"10.1016\/j.jphs.2025.05.018_bib13","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1111\/bph.14121","article-title":"Mirabegron: potential off target effects and uses beyond the bladder","volume":"175","author":"Dehvari","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.018_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bph.13379","article-title":"How \u03b23-adrenoceptor-selective is mirabegron?","volume":"173","author":"Michel","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.018_bib15","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1111\/bph.14658","article-title":"\u03b23-Adrenoceptors in the normal and diseased urinary bladder-what are the open questions?","volume":"176","author":"Igawa","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.018_bib16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coph.2014.03.003","article-title":"The pharmacological rationale for combining muscarinic receptor antagonists and \u03b2-adrenoceptor agonists in the treatment of airway and bladder disease","volume":"16","author":"Dale","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jphs.2025.05.018_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.120.000301","article-title":"Possible involvement of muscarinic receptor blockade in mirabegron therapy for patients with overactive bladder","volume":"377","author":"Yamada","year":"2021","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2025.05.018_bib18","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/iju.14696","article-title":"Muscarinic receptor binding activity in rat tissues by vibegron and prediction of its receptor occupancy levels in the human bladder","volume":"28","author":"Yamada","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.jphs.2025.05.018_bib19","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY Study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.jphs.2025.05.018_bib20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.jphs.2025.05.018_bib21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.jphs.2025.05.018_bib22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.molbrainres.2004.09.012","article-title":"Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice","volume":"133","author":"Oki","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"10.1016\/j.jphs.2025.05.018_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0022-5347(05)00017-0","article-title":"Human muscarinic receptor binding characteristics of antimuscarinic agents to treat overactive bladder","volume":"175","author":"Maruyama","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.jphs.2025.05.018_bib24","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1016\/j.clinthera.2012.09.010","article-title":"Pharmacokinetic properties of mirabegron, a \u03b23-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women","volume":"34","author":"Krauwinkel","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.jphs.2025.05.018_bib25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1124\/jpet.121.001029","article-title":"Inhibition of full smooth muscle contraction in isolated human detrusor tissues by mirabegron is limited to off-target inhibition of neurogenic contractions","volume":"381","author":"Huang","year":"2022","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.jphs.2025.05.018_bib26","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1159\/000515992","article-title":"Mirabegron versus solifenacin in children with overactive bladder: prospective randomized single-blind controlled trial","volume":"105","author":"Soliman","year":"2021","journal-title":"Urol Int"},{"key":"10.1016\/j.jphs.2025.05.018_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4111\/icu.2017.58.4.261","article-title":"Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy","volume":"58","author":"Shin","year":"2017","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.jphs.2025.05.018_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/ggi.14706","article-title":"Pharmacokinetic and pharmacodynamic consideration for the anticholinergic burden scale of drugs","volume":"24","author":"Yamada","year":"2024","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.jphs.2025.05.018_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/luts.12285","article-title":"Cognitive burden and polypharmacy in elderly Japanese patients treated with anticholinergics for an overactive bladder","volume":"12","author":"Shiota","year":"2020","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.jphs.2025.05.018_bib30","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2174\/138920011796504527","article-title":"Age-related changes in pharmacokinetics","volume":"12","author":"Shi","year":"2011","journal-title":"Curr Drug Metabol"},{"key":"10.1016\/j.jphs.2025.05.018_bib31","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/CIA.S252852","article-title":"Cognitive effects of anticholinergic load in women with overactive bladder","volume":"15","author":"Araklitis","year":"2020","journal-title":"Clin Interv Aging"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861325000635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:48:26Z","timestamp":1750398506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861325000635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1347861325000635"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2025.05.018","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Additive effects of mirabegron on muscarinic receptor binding and on relaxation of cholinergic detrusor muscle contraction by antimuscarinics","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2025.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}